Compare Gilead Sciences, Inc. (GILD) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nuscale Power Corporation — how do they compare? Gilead Sciences, Inc. trades at $135.97 (market cap $168.35B), while Nuscale Power Corporation trades at $9.79 (market cap $4.06B). The key difference: Gilead Sciences, Inc. is far larger — about 41.5× Nuscale Power Corporation's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| GILD | SMR | |
|---|---|---|
Market Cap | $168.35B | $4.06B |
Sector | Health | Utilities |
52-Week High | $155.80 | $53.43 |
52-Week Low | $110.56 | $7.59 |
Enterprise Value | $191.42B | $2.99B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
SMR stock trades at $9.55, up 4.03% today, with a bullish technical signal from moving averages. The company reported a net loss of $355.79M on $31.48M revenue in 2025, with negative profit margins. Recent news highlights regulatory progress for its small modular reactor technology and potential from AI data center power demand.
Outlook hinges on commercial deployment success; high risk from persistent losses and execution challenges, but Wall Street consensus price target of $10.50 suggests moderate upside. Investor sentiment is divided, with 50% of analysts rating Buy amid significant financial volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
